Fresenius announces FDA and EMA acceptance for vedolizumab biosimilar
The proposed biosimilar PB016 targets inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
Stay informed with the latest news and media coverage for the biggest companies in Healthcare Facilities & Services. We track all announcements, press releases, and industry mentions in real time, all in one place. Looking for another sector? Browse our industry database.
Last updated
The proposed biosimilar PB016 targets inflammatory bowel diseases like ulcerative colitis and Crohn's disease.
The evaluation compared three vendors across clinical, financial, operational, and partnership metrics, with Abridge outperforming.
Revenue fell 11% year-over-year to $190.7 million, with initiatives to improve efficiency and scalability.
Revenue increased 5.8% to $3.73 billion, adjusted EPS up 14.9% to $4.99.
Unlock all announcements with a free trial
Fresenius receives approval for biosimilar candidate PB016 in the USA and EU. At the same time, the dialysis subsidiary starts a US research program.
Myriad Genetics Inc. MYGN shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating...
Myriad Genetics lowered its full-year revenue guidance, as second quarter sales fell due to volume challenges in prenatal health and increased payer friction. The genetic...
Labcorp (LH) Q2 2026 earnings call recap: revenue +6%, margin expansion, raised 2026 EPS to $18.10–$...
Unlock all articles with a free trial
Track Every Market Move
Follow your target companies and get daily news updates delivered straight to your inbox
Start for freeBrowse the top companies in Healthcare Facilities & Services and stay on top of their latest developments.